BR112013005673A2 - uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes - Google Patents

uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes

Info

Publication number
BR112013005673A2
BR112013005673A2 BR112013005673A BR112013005673A BR112013005673A2 BR 112013005673 A2 BR112013005673 A2 BR 112013005673A2 BR 112013005673 A BR112013005673 A BR 112013005673A BR 112013005673 A BR112013005673 A BR 112013005673A BR 112013005673 A2 BR112013005673 A2 BR 112013005673A2
Authority
BR
Brazil
Prior art keywords
acid lipase
lysosomal acid
deficiency
treatment
lal
Prior art date
Application number
BR112013005673A
Other languages
English (en)
Other versions
BR112013005673B1 (pt
Inventor
Quinn Anthony
Original Assignee
Synageva Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45806910&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013005673(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2011/033699 external-priority patent/WO2011133960A2/en
Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp
Priority to BR122019021757-2A priority Critical patent/BR122019021757B1/pt
Publication of BR112013005673A2 publication Critical patent/BR112013005673A2/pt
Publication of BR112013005673B1 publication Critical patent/BR112013005673B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01013—Sterol esterase (3.1.1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lissomalem pacientes. a presente invenção provê tratamento de deficiência de lal (por exemplo, doença de wolman, cesd) compreendendo administrar a um mamífero uma quantidade terapeuticamente eficaz de lipase de ácido lisossomal com uma frequência de dosagem eficaz. métodos de aperfeiçoamento de crescimento e função hepática, aumento da concentração de lal no tecido e aumento da atividade de lal em um paciente humano sofrendo de deficiênte de lal são também providos.
BR112013005673-8A 2010-09-09 2011-09-09 Uso de lipase ácida lisossomal (lal) humana recombinante no tratamento da deficiência de lipase ácida lisossomal BR112013005673B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019021757-2A BR122019021757B1 (pt) 2010-09-09 2011-09-09 composição farmacêutica para tratamento de um paciente humano sofrendo de uma deficiência de lipase ácida lisossomal (lal)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40301110P 2010-09-09 2010-09-09
US61/403,011 2010-09-09
US45601410P 2010-10-29 2010-10-29
US61/456,014 2010-10-29
US201161432372P 2011-01-13 2011-01-13
US61/432,372 2011-01-13
PCT/US2011/033699 WO2011133960A2 (en) 2010-04-23 2011-04-23 Lysosomal storage disease enzyme
USPCT/US2011/033699 2011-04-23
PCT/US2011/051096 WO2012050695A1 (en) 2010-09-09 2011-09-09 Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients

Publications (2)

Publication Number Publication Date
BR112013005673A2 true BR112013005673A2 (pt) 2017-09-19
BR112013005673B1 BR112013005673B1 (pt) 2020-12-15

Family

ID=45806910

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013005673-8A BR112013005673B1 (pt) 2010-09-09 2011-09-09 Uso de lipase ácida lisossomal (lal) humana recombinante no tratamento da deficiência de lipase ácida lisossomal
BR122019021757-2A BR122019021757B1 (pt) 2010-09-09 2011-09-09 composição farmacêutica para tratamento de um paciente humano sofrendo de uma deficiência de lipase ácida lisossomal (lal)

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019021757-2A BR122019021757B1 (pt) 2010-09-09 2011-09-09 composição farmacêutica para tratamento de um paciente humano sofrendo de uma deficiência de lipase ácida lisossomal (lal)

Country Status (30)

Country Link
US (5) US8663631B2 (pt)
EP (3) EP2977057B1 (pt)
JP (3) JP5693728B2 (pt)
KR (1) KR20150038636A (pt)
CN (2) CN103200958A (pt)
AR (1) AR082953A1 (pt)
AU (1) AU2011314293B2 (pt)
BR (2) BR112013005673B1 (pt)
CA (2) CA2810999C (pt)
CL (1) CL2013000664A1 (pt)
CO (1) CO6710913A2 (pt)
CY (1) CY1116544T1 (pt)
DK (2) DK2613798T4 (pt)
ES (2) ES2535605T5 (pt)
HK (2) HK1220907A1 (pt)
HR (1) HRP20150438T1 (pt)
HU (1) HUE048688T2 (pt)
IL (2) IL225095A (pt)
ME (1) ME02062B (pt)
MX (2) MX365007B (pt)
NZ (3) NZ715014A (pt)
PL (2) PL2613798T5 (pt)
PT (2) PT2977057T (pt)
RS (1) RS53947B1 (pt)
RU (1) RU2550961C2 (pt)
SG (2) SG10201507199UA (pt)
SI (2) SI2977057T1 (pt)
SM (1) SMT201500108B (pt)
TW (1) TWI482625B (pt)
WO (1) WO2012050695A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2328446T5 (es) * 2000-02-04 2014-02-27 Children's Hospital Research Foundation Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
EP3205351B1 (en) 2010-04-23 2023-04-12 Alexion Pharmaceuticals, Inc. Lysosomal storage disease enzyme
MX365007B (es) 2010-09-09 2019-05-20 Alexion Pharmaceuticals Inc Star Uso de acido lipasa lisosomal para tratar la dificiencia de acido lipasa lisosomal en pacientes.
KR20140006037A (ko) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 리소좀의 산 리파제 결핍을 치료하는 방법들
WO2013055888A2 (en) 2011-10-12 2013-04-18 Synageva Biopharma Corp. Recombinant human naglu protein and uses thereof
KR20140130443A (ko) * 2012-03-02 2014-11-10 시나게바 바이오파르마, 코포레이션 절두된 리소좀 산 리파제
CN106885910B (zh) * 2015-12-15 2018-12-21 上海吉涛生物科技有限公司 肿瘤易感微环境检测装置及试剂盒
US11235036B2 (en) 2016-06-17 2022-02-01 Alexion Pharmaceuticals, Inc. Lysosomal acid lipase deficiency compositions and methods
WO2018039163A1 (en) 2016-08-23 2018-03-01 Alexion Pharmaceuticals, Inc. Method of purifying a heterologous protein from an egg white
US10633705B2 (en) 2016-10-14 2020-04-28 Alexion Pharmaceuticals, Inc. N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
US11396499B2 (en) 2018-12-12 2022-07-26 University Of Washington Lysosomal acid lipase assay
WO2021117122A1 (ja) * 2019-12-10 2021-06-17 株式会社リボルナバイオサイエンス ライソゾーム酸性リパーゼ欠損症の予防または治療剤

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001985D0 (sv) 1990-06-01 1990-06-01 Astra Ab New chemical products
WO1992016212A1 (en) 1991-03-13 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996004001A1 (en) 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
DE69637875D1 (de) 1995-09-14 2009-04-30 Virginia Tech Intell Prop Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen
CN1268741C (zh) 1996-09-13 2006-08-09 超卡里奥迪克治疗学股份有限公司 半乳糖苷酶a缺乏症的治疗
ES2268799T3 (es) 1997-10-29 2007-03-16 Genzyme Corporation Terapia genica para la enfermedad de gaucher.
US7339033B2 (en) 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
PT1137762E (pt) 1998-12-07 2009-01-14 Genzyme Corp Tratamento da doença de pompe
US7033780B1 (en) 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
ES2328446T5 (es) * 2000-02-04 2014-02-27 Children's Hospital Research Foundation Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2002036754A2 (en) * 2000-10-31 2002-05-10 Bayer Aktiengesellschaft Nucleotide and polypeptide sequence of human lysosomal acid lipase
US20030064437A1 (en) 2000-11-15 2003-04-03 Nick Wan Expression system for recombinant proteins
US20020193303A1 (en) 2001-01-25 2002-12-19 Millennium Pharmaceuticals, Inc. 58860, a human cholesteryl ester hydrolase and uses therefor
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
WO2003064614A2 (en) 2002-01-30 2003-08-07 Yale University Transport peptides and uses therefor
CA2482686C (en) 2002-04-16 2012-04-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A marker for measuring liver cirrhosis
CA2499188A1 (en) 2002-09-27 2004-04-08 Cold Spring Harbor Laboratory Cell-based rna interference and related methods and compositions
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2006002053A2 (en) 2004-06-15 2006-01-05 Mayo Foundation For Medical Education And Research Helicases
EP1784203B1 (en) 2004-08-19 2010-06-30 Biogen Idec MA Inc. Refolding transforming growth factor beta family proteins
US20070270367A1 (en) 2005-05-18 2007-11-22 University Of Kentucky Research Foundation Rybozyme-catalyzed insertion of targeted sequences into RNA
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
PL377180A1 (pl) 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
CA2622074C (en) 2005-10-05 2013-01-22 Avigenics, Inc. Rapid production of high titer virus
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US20070267249A1 (en) 2006-05-18 2007-11-22 Cullen David P Roof safety system
US8748567B2 (en) 2006-05-22 2014-06-10 Children's Medical Center Corporation Method for delivery across the blood brain barrier
EP2037945A4 (en) 2006-05-24 2012-07-04 Myelin Repair Foundation Inc PERMEABILITY OF THE HEMATO-ENCEPHALIC BARRIER
US8143265B2 (en) 2007-04-16 2012-03-27 Meharry Medical College Method of treating atherosclerosis
WO2008131431A2 (en) 2007-04-23 2008-10-30 St. Louis University Modulation of blood brain barrier protein expression
US8956825B2 (en) 2007-05-24 2015-02-17 The United States Of America As Represented By The Department Of Veterans Affairs Intranuclear protein transduction through a nucleoside salvage pathway
NZ599928A (en) 2007-05-31 2012-08-31 Glycan Biosciences Use of pentosan polysulfate for treatment or prophylaxis of asthma
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
WO2009032171A1 (en) 2007-08-29 2009-03-12 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
JP5571576B2 (ja) 2008-01-07 2014-08-13 シナジェバ・バイオファーマ・コーポレイション トリにおけるグリコシル化
WO2010033854A2 (en) 2008-09-19 2010-03-25 Synageva Biopharma Corp. Avian derived fusion proteins
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
US8183003B2 (en) 2009-01-02 2012-05-22 Zacharon Pharmaceuticals, Inc. Polymer end group detection
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
WO2011000958A1 (en) 2009-07-03 2011-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
US20110033699A1 (en) 2009-07-23 2011-02-10 Nitto Denko Corporation Pressure-sensitive adhesive tape
PL2995306T4 (pl) 2009-10-19 2019-07-31 Amicus Therapeutics, Inc. Nowe kompozycje do zapobiegania i/lub leczenia lizosomalnych zaburzeń spichrzeniowych
KR101077618B1 (ko) 2009-11-13 2011-10-27 경북대학교 산학협력단 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
US20150030582A1 (en) 2010-04-23 2015-01-29 Synageva Biopharma Corp. Lysosomal Storage Disease Enzyme
EP3205351B1 (en) 2010-04-23 2023-04-12 Alexion Pharmaceuticals, Inc. Lysosomal storage disease enzyme
MX365007B (es) 2010-09-09 2019-05-20 Alexion Pharmaceuticals Inc Star Uso de acido lipasa lisosomal para tratar la dificiencia de acido lipasa lisosomal en pacientes.
KR20140006037A (ko) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 리소좀의 산 리파제 결핍을 치료하는 방법들
WO2012112677A2 (en) 2011-02-15 2012-08-23 Children's Hospital Medical Center Methods for treating lysosomal acid lipase deficiency
CN103492574B (zh) 2011-02-22 2015-12-09 加州理工学院 使用腺相关病毒（aav）载体递送蛋白
US10227387B2 (en) 2011-05-18 2019-03-12 Children's Hospital Medical Center Targeted delivery of proteins across the blood-brain barrier
EP2721151B1 (en) 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
WO2012177639A2 (en) 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
US20130027021A1 (en) 2011-07-28 2013-01-31 Abb Inc. Current sensor
CN103842517A (zh) 2011-08-03 2014-06-04 莲花组织修复公司 胶原蛋白7及相关方法
WO2013055888A2 (en) 2011-10-12 2013-04-18 Synageva Biopharma Corp. Recombinant human naglu protein and uses thereof

Also Published As

Publication number Publication date
TW201225971A (en) 2012-07-01
EP2977057B1 (en) 2019-11-06
EP2977057A1 (en) 2016-01-27
JP2015052014A (ja) 2015-03-19
US20140348752A1 (en) 2014-11-27
JP6156882B2 (ja) 2017-07-05
BR112013005673B1 (pt) 2020-12-15
EP2613798A1 (en) 2013-07-17
ES2535605T3 (es) 2015-05-13
US20120064055A1 (en) 2012-03-15
US20160051638A1 (en) 2016-02-25
CO6710913A2 (es) 2013-07-15
DK2613798T3 (en) 2015-04-20
SI2613798T2 (en) 2018-05-31
US11400141B2 (en) 2022-08-02
US20190282671A1 (en) 2019-09-19
AU2011314293A1 (en) 2013-04-04
CA2810999A1 (en) 2012-04-19
US20220362350A1 (en) 2022-11-17
RS53947B1 (en) 2015-08-31
CY1116544T1 (el) 2018-03-07
US10166274B2 (en) 2019-01-01
MX365007B (es) 2019-05-20
TWI482625B (zh) 2015-05-01
IL245283A0 (en) 2016-06-30
HK1220907A1 (zh) 2017-05-19
HRP20150438T1 (hr) 2015-05-22
EP2613798B2 (en) 2018-01-24
EP3650039A1 (en) 2020-05-13
RU2013110491A (ru) 2014-11-10
PL2613798T3 (pl) 2015-07-31
IL245283B (en) 2019-02-28
CN105457018A (zh) 2016-04-06
HUE048688T2 (hu) 2020-08-28
PL2613798T5 (pl) 2018-06-29
ES2535605T5 (es) 2018-04-30
JP5693728B2 (ja) 2015-04-01
NZ608292A (en) 2014-10-31
DK2613798T4 (en) 2018-04-16
CN103200958A (zh) 2013-07-10
IL225095A (en) 2016-05-31
DK2977057T3 (da) 2020-02-10
AU2011314293B2 (en) 2015-06-04
HK1215532A1 (zh) 2016-09-02
JP2013540733A (ja) 2013-11-07
AR082953A1 (es) 2013-01-23
SG10201507199UA (en) 2015-10-29
BR122019021757B1 (pt) 2020-12-08
CL2013000664A1 (es) 2013-10-04
PL2977057T3 (pl) 2020-06-01
KR20150038636A (ko) 2015-04-08
WO2012050695A1 (en) 2012-04-19
ES2769836T3 (es) 2020-06-29
PT2613798E (pt) 2015-06-02
CA2810999C (en) 2023-10-03
PT2977057T (pt) 2020-02-18
SG188456A1 (en) 2013-04-30
RU2550961C2 (ru) 2015-05-20
JP2016145257A (ja) 2016-08-12
SI2977057T1 (sl) 2020-03-31
CA3209456A1 (en) 2012-04-19
NZ700824A (en) 2016-03-31
NZ715014A (en) 2018-10-26
US8663631B2 (en) 2014-03-04
SMT201500108B (it) 2015-07-09
SI2613798T1 (sl) 2015-05-29
ME02062B (me) 2015-05-20
EP2613798B1 (en) 2015-02-11
MX2013002704A (es) 2013-09-13

Similar Documents

Publication Publication Date Title
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
MX2009012197A (es) Metodos para tratamiento de ulceras en la piel.
BRPI0411856A (pt) composições e métodos para o aumento da atividade de telomerase
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
EP2392363A3 (en) Drug coated expandable devices
MY171356A (en) Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
BRPI0921845A2 (pt) formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
EP4124346A3 (en) Compositions and methods for treating diseases
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BRPI0418157A (pt) terapêutica de tumores alogênicos
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
BR112014011336A2 (pt) composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele
BR112012011316A2 (pt) tivozanib e temsirolimus em combinação
PT1585513E (pt) Utilizacao de acido docosa-hexaenoico como substancia activa para o tratamento de lipodistrofia
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
EA201270551A1 (ru) Лечение нейротоксичности, ассоциированной с комбинациями 5-fu или его пролекарств с ингибиторами dpd
FR2884423B1 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
UA109672C2 (uk) Застосування кислої лізосомної ліпази для лікування дефіциту кислої лізосомної ліпази у хворих

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALEXION PHARMA LLC (US)

B25A Requested transfer of rights approved

Owner name: ALEXION PHARMACEUTICALS, INC. (US)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/09/2011, OBSERVADAS AS CONDICOES LEGAIS.